ProfessorJaneApperley

Cross NCP, Ernst T, Branford S, et al.Cross NCP, Ernst T, Branford S, Cayuela J-M, Deininger M, Fabarius A, Kim DDH, Machova Polakova K, Radich JP, Hehlmann R, Hochhaus A, Apperley JF, Soverini S close, 2023, European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia, Leukemia, Vol:37, ISSN:0887-6924, Pages:2150-2167

• DOI
• Publisher Web Link
• Open Access Link

Ortí G, Gras L, Koster L, et al.Ortí G, Gras L, Koster L, Kulagin A, Byrne J, Apperley JF, Halaburda K, Blau IW, Clark A, Kröger N, Griskevicius L, Carlson K, Collin M, Bloor A, Raiola AM, Blaise D, Aljurf M, López-Corral L, Sakellari I, Beguin Y, Wrobel T, de Rosa L, de Lavallade H, Hayden PJ, McLornan D, Chalandon Y, Yakoub-Agha I close, 2023, Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)., Transplant Cell Ther

• DOI
• Author Web Link

Apperley J, Cortes J, Jabbour E, et al.Apperley J, Cortes J, Jabbour E, Hochhaus A, Hughes T, Chuah C, de Lavallade H, Deininger M, Lipton JH, Lomaia E, Maness L, Mauro M, McCloskey J, Moiraghi B, Pavlovsky C, Rojas C, Rousselot P, Sacha T, Talpaz M, Turkina A, Sutton MU, Ren X, Vorog A, Rosti G close, 2023, Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial, CIG MEDIA GROUP, LP, Pages:S339-S339, ISSN:2152-2650

• Author Web Link

Mauro M, Hochhaus A, Hughes T, et al.Mauro M, Hochhaus A, Hughes T, Rea D, Boquimpani C, Minami Y, Apperley J, Garcia-Gutierrez V, Kapoor S, Espurz N, Dhamal V, Cortes J close, 2023, Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study, CIG MEDIA GROUP, LP, Pages:S340-S340, ISSN:2152-2650

• Author Web Link

Cortes J, Deininger M, Lomaia E, et al.Cortes J, Deininger M, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, Chuah C, Sacha T, Lipton JH, McCloskey J, Rousselot P, Rosti G, de Lavallade H, Rojas C, Turkina A, Talpaz M, Mauro M, Lu V, Vorog A, Apperley J close, 2023, Post Hoc Analysis of Patient Responses by T315I Mutation Status From the 3-Year Update of the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib, CIG MEDIA GROUP, LP, Pages:S338-S338, ISSN:2152-2650

• Author Web Link